Skip to main content

Table 1 Comparison of clinicopathological characteristics before and after PSM in surgical group

From: Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study

Patient Characteristics Unmatched comparison Matched comparison
Patients with NEC components (n = 117) Gastric adenocarcinoma (n = 308) P value Patients with NEC components (n = 88) Gastric adenocarcinoma (n = 128) P value
Age (year), mean ± SD 61.7 ± 9.4 55.2 ± 10.8 < 0.001 59.7 ± 9.4 58.9 ± 9.7 0.551
Gender (male/female) 100/17 282/26 0.063 76/12 112/16 0.807
BMI, mean ± SD 24.1 ± 3.1 23.6 ± 3.6 0.100 24.4 ± 3.1 23.8 ± 3.6 0.182
Adjuvant therapy    < 0.001    0.189
 Yes 87 (74.4) 109 (35.4)   58 (65.9) 73 (57.0)  
 No 30 (25.6) 199 (64.6)   30 (34.1) 55 (43.0)  
Tumor location    < 0.001    0.679
 Upper third 70 (59.8) 74 (24.0)   46 (52.3) 60 (46.9)  
 Middle third 18 (15.4) 41 (13.3)   14 (15.9) 19 (14.8)  
 Lower third 28 (23.9) 192 (62.3)   28 (31.8) 48 (37.5)  
 Entire 1 (0.9) 1 (0.3)   0 (0.0) 1 (0.8)  
Tumor size    0.023    0.669
 < 5 cm 80 (68.4) 243 (78.9)   63 (71.6) 95 (74.2)  
 ≥ 5 cm 37 (31.6) 65 (21.1)   25 (28.4) 33 (25.8)  
Type of gastrectomy    < 0.001    0.077
 Total gastrectomy 78 (66.7) 79 (25.6)   53 (60.2) 59 (46.1)  
 Distal gastrectomy 29 (24.8) 206 (66.9)   29 (33.0) 51 (39.8)  
 Proximal gastrectomy 10 (8.5) 23 (7.5)   6 (6.8) 18 (14.1)  
Surgical procedure    < 0.001    0.001
 Open 106 (90.6) 212 (68.6)   80 (90.9) 92 (71.9)  
 Laparoscopic 11 (9.4) 96 (32.2)   8 (9.1) 36 (28.1)  
T stage    < 0.001    < 0.001
 T1 16 (13.7) 195 (63.3)   14 (15.9) 53 (41.4)  
 T2 26 (22.2) 18 (5.8)   25 (28.4) 12 (9.4)  
 T3 48 (41.0) 49 (15.9)   27 (30.7) 35 (27.3)  
 T4 27 (23.1) 46 (14.9)   22 (25.0) 28 (21.9)  
N stage    < 0.001    0.428
 N0 48 (41.0) 210 (68.2)   37 (42.0) 62 (48.4)  
 N1 32 (27.4) 26 (8.4)   22 (25.0) 22 (17.2)  
 N2 20 (17.1) 27 (8.8)   16 (18.2) 16 (18.2)  
 N3 17 (14.5) 45 (14.6)   13 (14.8) 24 (18.8)  
M stage    0.216    0.406
 M0 117 (100.0) 304 (98.7)   88 (100.0) 127 (99.2)  
 M1 0 (0.0) 4 (1.3)   0 (0.0) 1 (0.8)  
pTNM stage    < 0.001    0.399
 I 30 (25.6) 202 (65.6)   30 (34.1) 56 (43.8)  
 II 47 (40.2) 32 (10.4)   26 (29.5) 30 (23.4)  
 III 40 (34.2) 70 (22.7)   32 (36.4) 41 (32.0)  
 IV 0 (0.0) 4 (1.3)   0 (0.0) 1 (0.8)  
  1. BMI Body Mass Index, MiNEN Mixed neuroendocrine-non-neuroendocrine neoplasm, NEC neuroendocrine carcinoma, PSM Propensity Score Matching
  2. Patients with NEC components: NEC, < 30% high grade MiNEN, high grade MiNEN and > 70% high grade MiNEN